Predicting drug-drug interactions due to tyrosine kinase inhibitors: Inhibition of drug metabolising enzymes and transporters

预测酪氨酸激酶抑制剂引起的药物相互作用：药物代谢酶和转运蛋白的抑制

• 批准号: nhmrc : 1044063
• 负责人: Dr Andrew Rowland
• 金额: $ 35.71万
• 依托单位: Flinders University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/predicting-drug-drug-enzymes-transporters/111629
• 关键词: Predicting; drug; interactions; due; tyrosine

Tyrosine kinase inhibitors (TKIs) are a new class of anticancer agents. Cancer patients typically receive multiple drugs, for the treatment of cancer and other diseases, increasing the probability of interactions between coadministered drugs. Despite the widespread use of TKIs, their potential to cause drug interactions is poorly understood. Using novel in vitro approaches, this project will identify drug interactions precipitated by TKIs thereby improving drug efficacy and patient safety.

酪氨酸激酶抑制剂（TKI）是一类新型的抗癌药物。癌症患者通常接受多种药物，用于治疗癌症和其他疾病，增加了共同施用的药物之间相互作用的可能性。尽管TKI被广泛使用，但其引起药物相互作用的潜力仍知之甚少。使用新的体外方法，该项目将确定由TKI引起的药物相互作用，从而提高药物疗效和患者安全性。